keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis B virus

keyword
https://www.readbyqxmd.com/read/29156827/hepatitis-c-virus-core-protein-potentiates-proangiogenic-activity-of-hepatocellular-carcinoma-cells
#1
Yu-Yun Shao, Min-Shu Hsieh, Han-Yu Wang, Yong-Shi Li, Hang Lin, Hung-Wei Hsu, Chung-Yi Huang, Chih-Hung Hsu, Ann-Lii Cheng
Increased angiogenic activity has been demonstrated in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), but the mechanism was unclear. To study the role of HCV core protein, we used tube formation and Matrigel plug assays to assess the proangiogenic activity of an HCC cell line, HuH7, and 2 of its stable clones-HuH7-core-high and HuH7-core-low, with high and low HCV core protein expression, respectively. In both assays, HuH7-core-high and HuH7-core-low cells dose-dependently induced stronger angiogenesis than control cells...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29156773/association-of-acyp2-and-mphosph6-genetic-polymorphisms-with-the-risk-of-hepatocellular-carcinoma-in-chronic-hepatitis-b-virus-carriers
#2
Yingai Zhang, Shunlan Wang, Xiaohong Wen, Shufang Zhang, Yijun Yang
Hepatocellular carcinoma (HCC) is the dominant histologic type of primary liver cancer, and hepatitis B virus (HBV) infection is one of the major causes of HCC in the chronic HBV. Our study was investigated the association between the polymorphisms of ACYP2 and MPHOSPH6 genes and the risk of HCC induced by HBV infection. A total of 490 subjects were divided into two groups: 248 HBV patients with HCC (Case group), and 242 HBV patients without HCC (Control group). Unconditional logistic regression analysis was used to evaluate the association...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29156567/the-role-of-infected-cell-proliferation-in-the-clearance-of-acute-hbv-infection-in-humans
#3
Ashish Goyal, Ruy M Ribeiro, Alan S Perelson
Around 90-95% of hepatitis B virus (HBV) infected adults do not progress to the chronic phase and, instead, recover naturally. The strengths of the cytolytic and non-cytolytic immune responses are key players that decide the fate of acute HBV infection. In addition, it has been hypothesized that proliferation of infected cells resulting in uninfected progeny and/or cytokine-mediated degradation of covalently closed circular DNA (cccDNA) leading to the cure of infected cells are two major mechanisms assisting the adaptive immune response in the clearance of acute HBV infection in humans...
November 18, 2017: Viruses
https://www.readbyqxmd.com/read/29156050/viral-factors-affecting-the-clinical-outcomes-of-chronic-hepatitis-b
#4
Hung-Chih Yang, Yi-Fen Shih, Chun-Jen Liu
Chronic hepatitis B (CHB) exhibits a variety of clinical outcomes, ranging from spontaneous resolution of hepatitis B to severe adverse consequences, including the development of cirrhosis, hepatic failure, and hepatocellular carcinoma. The heterogeneous clinical courses of chronic hepatitis B virus (HBV) infection reflect the complex host-virus interactions, and point to the difficulty and necessity of identifying the patients at risk. With the advance of HBV virology, several viral factors have been found to be associated with the long-term clinical outcomes of CHB patients...
November 16, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29156049/management-of-pregnant-women-and-children-focusing-on-preventing-mother-to-infant-transmission
#5
Huey-Ling Chen, Wan-Hsin Wen, Mei-Hwei Chang
Hepatitis B virus (HBV) immunization has been effectively preventing chronic HBV infection with >90% efficacy in countries with universal neonatal immunization. Perinatal mother-to-infant transmission of HBV remains the major cause of chronic HBV infection despite immunization. Maternal hepatitis B e-antigen (HBeAg) and high viral load have been noted to be the most important risk factors for transmission. In recent years, short-term antiviral therapy for pregnant women in the third trimester has been shown to be highly effective in reducing 90% of vaccine failure in children...
November 16, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29156048/unmet-needs-in-clinical-and-basic-hepatitis-b-virus-research
#6
Tung-Hung Su, Jia-Horng Kao
Chronic hepatitis B (CHB) has become a treatable and controllable disease. The current nucleos(t)ide analogue (NUC) and pegylated interferon therapies effectively help slow disease progression and reduce the risk of cirrhosis, hepatocellular carcinoma (HCC), and CHB-associated mortality. Long-term viral suppression is easily achievable by NUC therapy, with limited adverse reactions. However, several unmet requirements still exist, including safety and risk-stratified HCC surveillance among patients who received long-term NUC therapy...
November 16, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29156047/immunopathogenesis-of-hepatitis-b-virus
#7
Tai-Chung Tseng, Li-Rung Huang
Chronic hepatitis B virus (HBV) infection is a global public health issue. There are >250 million people chronically infected with HBV, and these chronic carriers are at high risk of developing end-stage liver diseases and hepatocellular carcinoma. Patients with chronic hepatitis B (CHB) usually acquire the virus perinatally, while most patients infected during adulthood develop acute hepatitis B (AHB), which usually results in viral clearance. HBV infection is noncytopathic, and liver injury is mostly contributed by host immune responses...
November 16, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29156046/toward-a-cure-for-hepatitis-b-virus-infection-combination-therapy-involving-viral-suppression-and-immune-modulation-and-long-term-outcome
#8
Di Wu, Qin Ning
Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, the approved therapeutic regimens include nucleos(t)ide analogues (NAs) and either interferon or pegylated interferon. NA therapy is generally safe and well tolerated, but the rate of posttreatment virologic relapse is high, making NA treatment a lifetime commitment. The benefits of pegylated interferon treatment include a finite duration, more-durable response and absence of viral resistance. However, sustained response to interferon alone is achieved only in a minority of patients, and side effects are common, which limit its clinical use...
November 16, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29156045/nohep-toward-global-control-of-hepatitis-b-virus-infection-an-introduction
#9
Chun-Jen Liu, Jia-Horng Kao
No abstract text is available yet for this article.
November 16, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29156044/characteristics-prevention-and-management-of-hepatitis-b-virus-hbv-reactivation-in-hbv-infected-patients-who-require-immunosuppressive-therapy
#10
Jonggi Choi, Young-Suk Lim
Hepatitis B virus (HBV) reactivation becomes a challenging issue with increasing use of immunosuppressive agents and cytotoxic chemotherapy for varied medical conditions, including cancer. The spectrum of HBV reactivation in the setting of immunosuppression may vary from asymptomatic reactivation to liver failure leading to death. HBV reactivation can hamper the course of planned therapies and diminish the effects of therapies; thus, it adversely affects the prognosis of the original disease and the survival of the patients...
November 16, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29155019/the-risk-of-hepatocellular-carcinoma-in-cirrhotic-patients-with-hepatitis-c-and-sustained-viral-response-role-of-the-treatment-regimen
#11
Hamish Innes, Stephen T Barclay, Peter C Hayes, Andrew Fraser, John F Dillon, Adrian Stanley, Andy Bathgate, Scott A McDonald, David Goldberg, Heather Valerio, Ray Fox, Nick Kennedy, Pete Bramley, Sharon J Hutchinson
BACKGROUND: Previous studies have reported a high frequency of hepatocellular carcinoma (HCC) occurrence in patients with advanced liver disease, after receipt of interferon(IFN)-free therapy for hepatitis C virus (HCV) infection. Our objective was to verify and account for this phenomenon using data from the Scottish HCV Clinical Database. METHODS: We identified HCC-naïve individuals with liver cirrhosis receiving a course of antiviral therapy in Scotland from 1997-2016 resulting in a SVR...
November 15, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29152828/efficacy-and-safety-of-12-weeks-of-elbasvir-%C3%A2-grazoprevir-%C3%A2-ribavirin-in-participants-with-hcv-genotype-2-4-5-or-6-infection-the-c-scape-study
#12
A Brown, C Hézode, E Zuckerman, G R Foster, A Zekry, S K Roberts, F Lahser, C Durkan, C Badshah, B Zhang, M Robertson, J Wahl, E Barr, B Haber
People with hepatitis C virus (HCV) infection other than genotype 1 represent a heterogeneous group. The aim of the phase 2 C-SCAPE study was to evaluate elbasvir/grazoprevir (EBR/GZR), with or without ribavirin (RBV), in participants with HCV genotype 2, 4, 5 or 6 infection. This was a part randomized, open-label, parallel-group study (NCT01932762; PN047-03) of treatment-naive, non-cirrhotic participants. Participants with HCV genotype 2 infection received GZR 100 mg+RBV±EBR 50 mg for 12 weeks and those with genotype 4, 5 or 6 infection were randomized to receive EBR/GZR±RBV for 12 weeks...
November 20, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29151907/the-combination-of-anti-hbc-and-anti-hbs-levels-is-a-useful-predictor-of-the-development-of-chemotherapy-induced-reactivation-in-lymphoma-patients-with-resolved-hbv-infection
#13
Tokuhiro Matsubara, Tsutomu Nishida, Akiyoshi Shimoda, Hiromi Shimakoshi, Takahiro Amano, Aya Sugimoto, Kei Takahashi, Kaori Mukai, Masashi Yamamoto, Shiro Hayashi, Sachiko Nakajima, Koji Fukui, Masami Inada
Fatal chemotherapy-induced hepatitis B virus reactivation (HBV-R) is a well-described serious complication observed in patients with lymphoma and resolved HBV infection. The aim of the present study was to determine the predictive factors of the development of chemotherapy-induced HBV-R. A total of 77 consecutive newly diagnosed patients with lymphoma and resolved HBV infection, who received chemotherapy from 2007 through 2015 were analysed retrospectively. Significant predictive factors associated with HBV-R were identified based on the data from these patients...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29151700/tenofovir-vs-lamivudine-plus-adefovir-in-chronic-hepatitis-b-tenosimp-b-study
#14
Manuel Rodríguez, Juan Manuel Pascasio, Enrique Fraga, Javier Fuentes, Martín Prieto, Gloria Sánchez-Antolín, José Luis Calleja, Esther Molina, María Luisa García-Buey, María Ángeles Blanco, Javier Salmerón, María Lucía Bonet, José Antonio Pons, José Manuel González, Miguel Ángel Casado, Francisco Jorquera, The Tenosimp-B Research Group
AIM: To demonstrate the non-inferiority (15% non-inferiority limit) of monotherapy with tenofovir disoproxil fumarate (TDF) vs the combination of lamivudine (LAM) plus adefovir dipivoxil (ADV) in the maintenance of virologic response in patients with chronic hepatitis B (CHB) and prior failure with LAM. METHODS: This study was a Phase IV prospective, randomized, open, controlled study with 2 parallel groups (TDF and LAM+ADV) of adult patients with hepatitis B e antigen (HBeAg)-negative CHB, prior failure with LAM, on treatment with LAM+ADV for at least 6 mo, without prior resistance to ADV and with an undetectable viral load at the start of the study, in 14 Spanish hospitals...
November 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29151181/screening-hcv-genotype-specific-epitope-peptides-based-on-conserved-sequence-analysis-and-b-cell-epitope-prediction-in-hcv-e2-region
#15
Rui Hua, Xiaoyu Jiang, Lingxia Qi, Shanshan Guan, Ziyu Kuai, Yongbo Qiao, Yan Xu, Xin Gong, Yuhua Shi, Wei Kong, Junqi Niu, Hao Zhang, Yaming Shan
The high mutation rate of the hepatitis C virus (HCV) genome increases the genotype diversity and renders the detection of the virus more difficult. Therefore, prediction and assessment of highly conserved and strongly antigenic epitope polypeptide sequences have become a focus of current research. The E2 region is the target binding region of neutralizing antibodies. HCV genomics, especially the high mutation rate of E2 region sequence, makes its genotyping more and more diverse, and the detection of HCV and genotype is becoming more and more strict...
November 18, 2017: Immunologic Research
https://www.readbyqxmd.com/read/29149926/drug-induced-gastrointestinal-and-hepatic-disease-associated-with-biologics-and-nonbiologic-disease-modifying-antirheumatic-drugs
#16
REVIEW
Patrick R Wood, Liron Caplan
A variety of gastrointestinal adverse drug reactions are seen in nearly all conventional antirheumatic medications, ranging from nausea to life-threatening drug-induced liver injury. Rheumatologists should be particularly familiar with hepatotoxicity associated with long-term methotrexate use, and the range of unique hepatic, biliary, and pancreatic manifestations associated with azathioprine. Hepatitis B virus reactivation is the most serious gastrointestinal disease risk associated with many biological therapies, particularly rituximab...
February 2018: Rheumatic Diseases Clinics of North America
https://www.readbyqxmd.com/read/29149205/kir-content-genotypes-associate-with-carriage-of-hepatitis-b-surface-antigen-e-antigen-and-hbv-viral-load-in-gambians
#17
Louis-Marie Yindom, Maimuna Mendy, Christopher Bodimeade, Caroline Chambion, Peter Aka, Hilton C Whittle, Sarah L Rowland-Jones, Robert Walton
BACKGROUND: Hepatocellular carcinoma (HCC) causes over 800,000 deaths worldwide annually, mainly in low income countries, and incidence is rising rapidly in the developed world with the spread of hepatitis B (HBV) and C (HCV) viruses. Natural Killer (NK) cells protect against viral infections and tumours by killing abnormal cells recognised by Killer-cell Immunoglobulin-like Receptors (KIR). Thus genes and haplotypes encoding these receptors may be important in determining both outcome of initial hepatitis infection and subsequent chronic liver disease and tumour formation...
2017: PloS One
https://www.readbyqxmd.com/read/29149060/epigenetic-regulation-of-viral-biological-processes
#18
REVIEW
Lata Balakrishnan, Barry Milavetz
It is increasingly clear that DNA viruses exploit cellular epigenetic processes to control their life cycles during infection. This review will address epigenetic regulation in members of the polyomaviruses, adenoviruses, human papillomaviruses, hepatitis B, and herpes viruses. For each type of virus, what is known about the roles of DNA methylation, histone modifications, nucleosome positioning, and regulatory RNA in epigenetic regulation of the virus infection will be discussed. The mechanisms used by certain viruses to dysregulate the host cell through manipulation of epigenetic processes and the role of cellular cofactors such as BRD4 that are known to be involved in epigenetic regulation of host cell pathways will also be covered...
November 17, 2017: Viruses
https://www.readbyqxmd.com/read/29148393/new-avian-hepadnavirus-in-palaeognathous-bird-germany
#19
Wendy K Jo, Vanessa M Pfankuche, Henning Petersen, Samuel Frei, Maya Kummrow, Stephan Lorenzen, Martin Ludlow, Julia Metzger, Wolfgang Baumgärtner, Albert Osterhaus, Erhard van der Vries
In 2015, we identified an avian hepatitis B virus associated with hepatitis in a group of captive elegant-crested tinamous (Eudromia elegans) in Germany. The full-length genome of this virus shares <76% sequence identity with other avihepadnaviruses. The virus may therefore be considered a new extant avian hepadnavirus.
December 2017: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/29147645/real-world-cure-rates-for-hepatitis-c-virus-treatments-that-include-simeprevir-and-or-sofosbuvir-are-comparable-to-clinical-trial-results
#20
Kian Bichoupan, Neeta Tandon, James F Crismale, Joshua Hartman, David Del Bello, Neal Patel, Sweta Chekuri, Alyson Harty, Michel Ng, Keith M Sigel, Meena B Bansal, Priya Grewal, Charissa Y Chang, Jennifer Leong, Gene Y Im, Lawrence U Liu, Joseph A Odin, Nancy Bach, Scott L Friedman, Thomas D Schiano, Ponni V Perumalswami, Douglas T Dieterich, Andrea D Branch
AIM: To assess the real-world effectiveness and cost of simeprevir (SMV), and/or sofosbuvir (SOF)-based therapy for chronic hepatitis C virus (HCV) infection. METHODS: The real-world performance of patients treated with SMV/SOF ± ribavirin (RBV), SOF/RBV, and SOF/RBV with pegylated-interferon (PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included...
November 12, 2017: World Journal of Virology
keyword
keyword
12171
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"